,201 Inotersen, utilizing the Gapmer structure to target transthyretin (TTR) mRNA for the treatment of hereditary transthyretin (hATTR)-mediated amyloidosis, was successfully developed and approved by the FDA in 2018202 (Figure 3). The gene discussed is TTR; the disease is amyloidosis.